Kathawala et al. [28] reported that the compound, 2-trifluoromethyl-2-hydroxypropionamide, a benzamide derivative, decreased ABCG2-mediated resistance by inhibiting the efflux activity of ABCG, and increased the efficacy of mitoxantrone and SN-38 in NCI-H460/MX20 cancer cells. Here, ABCG2 is linked to cancer.